Genmab A/S (Genmab A/S) Market Cap : $18,232 Mil (As of Apr. 27, 2024)

View and export this data going back to . Start your Free Trial

What is Genmab A/S Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Genmab A/S's share price for the quarter that ended in Dec. 2023 was $315.7. Genmab A/S's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 65 Mil. Therefore, Genmab A/S's market cap for the quarter that ended in Dec. 2023 was $20,625 Mil.

Genmab A/S's quarterly market cap declined from Jun. 2023 ($24,454 Mil) to Sep. 2023 ($23,272 Mil) and declined from Sep. 2023 ($23,272 Mil) to Dec. 2023 ($20,625 Mil).

Genmab A/S's annual market cap increased from Dec. 2021 ($25,665 Mil) to Dec. 2022 ($27,946 Mil) but then declined from Dec. 2022 ($27,946 Mil) to Dec. 2023 ($20,625 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Genmab A/S's Enterprise Value for Today is $13,894 Mil.

Genmab A/S Market Cap Historical Data

The historical data trend for Genmab A/S's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Market Cap Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

14,042.76

27,375.59

25,665.05

27,946.36

20,624.81

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															27,946.36	24,376.91	24,453.64	23,271.88	20,624.81

Competitive Comparison of Genmab A/S's Market Cap

For the Biotechnology subindustry, Genmab A/S's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab A/S's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Market Cap distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Market Cap falls into.

Genmab A/S Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Genmab A/S's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$315.7	*	65.3304
	=	$20,625

Genmab A/S's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$315.7	*	65.3304
	=	$20,625

Genmab A/S (OTCPK:GNMSF) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Genmab A/S Market Cap Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.